Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial

Abstract

Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy.